SK283446B6 - Izolovaná DNA sekvencia, vektor, hostiteľská bunka, spôsob výroby homogénneho gp350 proteínu, farmaceutický prostriedok s jeho obsahom a jeho použitie - Google Patents

Izolovaná DNA sekvencia, vektor, hostiteľská bunka, spôsob výroby homogénneho gp350 proteínu, farmaceutický prostriedok s jeho obsahom a jeho použitie Download PDF

Info

Publication number
SK283446B6
SK283446B6 SK1343-96A SK134396A SK283446B6 SK 283446 B6 SK283446 B6 SK 283446B6 SK 134396 A SK134396 A SK 134396A SK 283446 B6 SK283446 B6 SK 283446B6
Authority
SK
Slovakia
Prior art keywords
thr
protein
ser
dna sequence
sequence
Prior art date
Application number
SK1343-96A
Other languages
English (en)
Slovak (sk)
Other versions
SK134396A3 (en
Inventor
Richard Spaete
Winthrop T. Jackman
Original Assignee
Medimmune Vaccines, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Vaccines, Inc. filed Critical Medimmune Vaccines, Inc.
Publication of SK134396A3 publication Critical patent/SK134396A3/sk
Publication of SK283446B6 publication Critical patent/SK283446B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Detergent Compositions (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Polarising Elements (AREA)
  • Paper (AREA)
SK1343-96A 1994-04-18 1995-04-13 Izolovaná DNA sekvencia, vektor, hostiteľská bunka, spôsob výroby homogénneho gp350 proteínu, farmaceutický prostriedok s jeho obsahom a jeho použitie SK283446B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22929194A 1994-04-18 1994-04-18
PCT/US1995/004611 WO1995028488A1 (en) 1994-04-18 1995-04-13 NON-SPLICING VARIANTS OF gp350/220

Publications (2)

Publication Number Publication Date
SK134396A3 SK134396A3 (en) 1997-06-04
SK283446B6 true SK283446B6 (sk) 2003-07-01

Family

ID=22860582

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1343-96A SK283446B6 (sk) 1994-04-18 1995-04-13 Izolovaná DNA sekvencia, vektor, hostiteľská bunka, spôsob výroby homogénneho gp350 proteínu, farmaceutický prostriedok s jeho obsahom a jeho použitie

Country Status (25)

Country Link
US (3) US6054130A (fi)
EP (1) EP0769056B1 (fi)
JP (4) JP3447743B2 (fi)
KR (1) KR100380953B1 (fi)
CN (2) CN1118573C (fi)
AT (1) ATE210184T1 (fi)
AU (1) AU707837B2 (fi)
BR (1) BR9507473A (fi)
CA (1) CA2187908C (fi)
CZ (1) CZ292283B6 (fi)
DE (1) DE69524415T2 (fi)
DK (1) DK0769056T3 (fi)
ES (1) ES2170144T3 (fi)
FI (2) FI118224B (fi)
HU (1) HU221647B1 (fi)
LV (1) LV11803B (fi)
MY (1) MY114769A (fi)
NO (1) NO319382B1 (fi)
PL (1) PL181881B1 (fi)
PT (1) PT769056E (fi)
RU (1) RU2178807C2 (fi)
SK (1) SK283446B6 (fi)
TW (1) TW496897B (fi)
UA (1) UA47403C2 (fi)
WO (1) WO1995028488A1 (fi)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6692749B1 (en) * 1994-04-18 2004-02-17 Medimmune Vaccines, Inc. Non-splicing variants of gp350/220
MY114769A (en) 1994-04-18 2003-01-31 Aviron Inc Non-splicing variants of gp350/220
AU2582897A (en) * 1996-03-15 1997-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
AUPO784197A0 (en) * 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
EP1036177A1 (en) * 1997-12-05 2000-09-20 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
AU762799B2 (en) 1998-06-12 2003-07-03 Henry M. Jackson Foundation For The Advancement Of Military Medicine Enhancement of B cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and EBV Gp350/220
GB0210682D0 (en) * 2002-05-09 2002-06-19 Glaxosmithkline Biolog Sa Novel use
EP2432793A4 (en) * 2009-05-22 2012-11-28 Intelligent Med Devices Inc OPTIMIZED PROBES AND PRIMERS, AND METHOD FOR USING THEM TO DETECT, SCREEN, QUANTIFY, INSOLATE, AND SEQUENCY THE CYTOMEGALOVIRUS AND EPSTEIN BARR VIRUS
US10461635B1 (en) * 2018-05-15 2019-10-29 Analog Devices Global Unlimited Company Low VIN high efficiency chargepump

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3069310D1 (en) * 1980-11-03 1984-10-31 Itt Ind Gmbh Deutsche Binary mos ripple carry parallel adder/subtractor and appropriate adding/subtracting stage
US4707358A (en) * 1984-01-30 1987-11-17 The University Of Chicago Vaccine against Epstein-Barr Virus
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
DE3583564D1 (de) * 1984-08-23 1991-08-29 Hans Joachim Wolf Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
EP0312164A1 (en) * 1987-10-16 1989-04-19 Merck & Co. Inc. Purification of recombinant epstein-barr virus antigens from vero cells, yeast cells or L cells
CA2090295A1 (en) * 1992-02-03 1993-08-04 Anthony B. Nesburn Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use
WO1993019092A1 (fr) * 1992-03-19 1993-09-30 Centre National De La Recherche Scientifique Adenovirus recombinants defectifs exprimant des proteines caracteristiques du virus epstein-barr
US5474914A (en) * 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
MY114769A (en) 1994-04-18 2003-01-31 Aviron Inc Non-splicing variants of gp350/220

Also Published As

Publication number Publication date
CN1152940A (zh) 1997-06-25
FI20075338A (fi) 2007-05-10
AU2383895A (en) 1995-11-10
DK0769056T3 (da) 2002-04-02
DE69524415D1 (de) 2002-01-17
HU221647B1 (hu) 2002-12-28
JPH10501687A (ja) 1998-02-17
NO964431L (no) 1996-12-11
CA2187908C (en) 2002-09-17
CZ305496A3 (en) 1997-10-15
LV11803B (en) 1998-01-20
ES2170144T3 (es) 2002-08-01
PL181881B1 (pl) 2001-09-28
FI964186A (fi) 1996-12-17
LV11803A (lv) 1997-06-20
JP2005333990A (ja) 2005-12-08
US6458364B1 (en) 2002-10-01
US6054130A (en) 2000-04-25
UA47403C2 (uk) 2002-07-15
BR9507473A (pt) 1997-09-23
EP0769056A4 (en) 1998-03-04
CN1495262A (zh) 2004-05-12
EP0769056A1 (en) 1997-04-23
AU707837B2 (en) 1999-07-22
JP3447743B2 (ja) 2003-09-16
NO964431D0 (no) 1996-10-18
CN100415895C (zh) 2008-09-03
DE69524415T2 (de) 2002-08-01
CA2187908A1 (en) 1995-10-26
JP4317786B2 (ja) 2009-08-19
JP2003230396A (ja) 2003-08-19
PT769056E (pt) 2002-05-31
ATE210184T1 (de) 2001-12-15
FI964186A0 (fi) 1996-10-18
SK134396A3 (en) 1997-06-04
CN1118573C (zh) 2003-08-20
HU9602894D0 (en) 1996-12-30
RU2178807C2 (ru) 2002-01-27
JP2004290199A (ja) 2004-10-21
CZ292283B6 (cs) 2003-08-13
MY114769A (en) 2003-01-31
US5824508A (en) 1998-10-20
PL316941A1 (en) 1997-02-17
TW496897B (en) 2002-08-01
KR100380953B1 (ko) 2003-10-10
HUT75831A (en) 1997-05-28
EP0769056B1 (en) 2001-12-05
FI118224B (fi) 2007-08-31
NO319382B1 (no) 2005-07-25
WO1995028488A1 (en) 1995-10-26

Similar Documents

Publication Publication Date Title
Wathen et al. Isolation, characterization, and physical mapping of a pseudorabies virus mutant containing antigenically altered gp50
Jackman et al. Expression of Epstein–Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine
AU742281B2 (en) Vaccine composition for herpes simplex virus and methods of using
EP0802979B1 (en) Secreted viral cmv proteins useful for vaccines and diagnostics
JP2005333990A (ja) ｇｐ３５０／２２０非スプライシング変異体
Fuchs et al. Structure-based mutational analysis of the highly conserved domain IV of glycoprotein H of pseudorabies virus
US5807557A (en) Soluble herpesvirus glycoprotein complex
US20130064844A1 (en) Non-splicing variants of gp350/220
Guo et al. Characterization of a structurally tricistronic gene of human cytomegalovirus composed of U (s) 18, U (s) 19, and U (s) 20
EP0471457A2 (en) Herpesvirus-based viral vector which expresses a foot & mouth disease virus epitope
EP0606452A1 (en) Vector vaccines of recombinant feline herpesvirus
WO1995009249A1 (en) Oral vaccination of mammals
WO1995029991A1 (en) A novel vzv gene, mutant vzv and immunogenic compositions
Moško et al. Expression of herpes simplex virus glycoprotein D in prokaryotic and eukaryotic cells
CA2246802C (en) A human cytomegalovirus combined antigen and its use
Heineman The Mapping of Epstein-Barr Virus Gp85 and the Identification of a Novel EBV Glycoprotein
Gong Characterization of a novel EBV glycoprotein GP110 and the role of EBV glycoproteins in viral egress

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20130413